Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New app aims to simplify kidney disease management for kids

NCT ID NCT04075656

Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a mobile app called UrApp designed to help families manage childhood nephrotic syndrome, a chronic kidney disease. 58 caregivers of children with the condition were randomly assigned to use the app or receive standard care for one year. The goal was to see if the app improved medication adherence and urine monitoring at home.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
UrApp mobile application
What this could lead to
If successful, this app could help families better manage nephrotic syndrome at home, potentially reducing relapses and complications.
What could go wrong
This is a small pilot study with only 58 participants. The app may not improve outcomes significantly, and results may not apply to all families.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

58 people

The number who actually took part.

Started

Sep 2019

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Caregivers of patients ages 1-17 with steroid sensitive nephrotic syndrome (clinical diagnosis with edema, nephrotic range proteinuria \[urine protein to creatinine ratio \>2 mg/mg, or ≥ 300 mg/dL or ≥ 3+ protein on urine dipstick\], and hypoalbuminemia ≤ 2.5 g/dL; resolution of proteinuria \[negative/trace protein on urine dipstick\] within 4 weeks of corticosteroid treatment) * Caregivers of pediatric patients with steroid sensitive nephrotic syndrome diagnosed within 42 days at the time of enrollment * Access to internet/wireless fidelity (Wi-Fi) in the home * Caregiver proficiency with the English language Exclusion Criteria: * Caregivers of pediatric patients with end-stage kidney disease * Caregivers of pediatric patients with renal transplantation * Caregivers of pediatric patients with clinical or histologic evidence of secondary nephrotic syndrome (e.g., systemic lupus erythematosus)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic nephrotic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic nephrotic syndrome lipoid nephrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic nephrotic syndrome

Contacts and locations

Locations

  • Children's Healthcare of Altanta

    Atlanta, Georgia, 30322, United States

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • University of Minnesota Children's Hospital

    Minneapolis, Minnesota, 55454, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.